Do analysts recommend ALGS or OSRH?

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 455.56%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALGS or OSRH more profitable?

Aligos Therapeutics has a net margin of -241.01% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Aligos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aligos Therapeutics -241.01% -160.72% -92.30% OSR -593.15% -8.36% -6.24%

Does the media favor ALGS or OSRH?

In the previous week, OSR had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 3 mentions for OSR and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.46 beat OSR's score of 0.03 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OSR 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer OSRH or MDXH?

MDxHealth has a consensus price target of $2.17, suggesting a potential upside of 192.28%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts clearly believe MDxHealth is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has better earnings and valuation, OSRH or MDXH?

OSR has higher earnings, but lower revenue than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OSR $2.91M 3.02 -$27.06M -$0.37 N/A MDxHealth $107.88M 0.34 -$33.52M -$0.72 N/A

Is OSRH or MDXH more profitable?

MDxHealth has a net margin of -33.46% compared to OSR's net margin of -593.15%. MDxHealth's return on equity of 0.00% beat OSR's return on equity. Company Net Margins Return on Equity Return on Assets OSR -593.15% -8.36% -6.24% MDxHealth -33.46% N/A -24.25%

Does the media prefer OSRH or MDXH?

In the previous week, MDxHealth had 4 more articles in the media than OSR. MarketBeat recorded 7 mentions for MDxHealth and 3 mentions for OSR. OSR's average media sentiment score of 0.03 beat MDxHealth's score of -0.18 indicating that OSR is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OSR 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MDxHealth 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate OSRH or RADX?

Radiopharm Theranostics has a consensus price target of $11.00, indicating a potential upside of 350.82%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Radiopharm Theranostics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better earnings and valuation, OSRH or RADX?

Radiopharm Theranostics has higher revenue and earnings than OSR. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OSR $2.91M 3.02 -$27.06M -$0.37 N/A Radiopharm Theranostics $3.63M 9.71 -$24.83M N/A N/A

Does the media prefer OSRH or RADX?

In the previous week, OSR had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 3 mentions for OSR and 2 mentions for Radiopharm Theranostics. OSR's average media sentiment score of 0.03 beat Radiopharm Theranostics' score of 0.00 indicating that OSR is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OSR 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer OSRH or BTAI?

BioXcel Therapeutics has a consensus target price of $11.00, indicating a potential upside of 1,346.23%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is OSRH or BTAI more profitable?

OSR has a net margin of -593.15% compared to BioXcel Therapeutics' net margin of -9,549.87%. BioXcel Therapeutics' return on equity of 0.00% beat OSR's return on equity. Company Net Margins Return on Equity Return on Assets OSR -593.15% -8.36% -6.24% BioXcel Therapeutics -9,549.87% N/A -185.82%

Do analysts recommend OSRH or GOSS?

Gossamer Bio has a consensus price target of $3.20, indicating a potential upside of 1,728.57%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gossamer Bio 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22

Which has stronger earnings and valuation, OSRH or GOSS?

OSR has higher earnings, but lower revenue than Gossamer Bio. OSR is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OSR $2.91M 3.02 -$27.06M -$0.37 N/A Gossamer Bio $53.29M 0.77 -$170.37M -$0.70 N/A

Is OSRH or GOSS more profitable?

Gossamer Bio has a net margin of -235.00% compared to OSR's net margin of -593.15%. Gossamer Bio's return on equity of 0.00% beat OSR's return on equity. Company Net Margins Return on Equity Return on Assets OSR -593.15% -8.36% -6.24% Gossamer Bio -235.00% N/A -112.04%

Does the media prefer OSRH or GOSS?

In the previous week, Gossamer Bio had 1 more articles in the media than OSR. MarketBeat recorded 4 mentions for Gossamer Bio and 3 mentions for OSR. Gossamer Bio's average media sentiment score of 0.42 beat OSR's score of 0.03 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OSR 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Gossamer Bio 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

OSR (OSRH) Competitors

$0.25 -0.03 (-9.75%)

Closing price 04:00 PM Eastern

Extended Trading

$0.22 -0.03 (-13.20%)

As of 05:33 PM Eastern

Compare

OSRH vs. ALGS, MDXH, RADX, BTAI, and GOSS

Should you buy OSR stock or one of its competitors? OSR's main competitors and comparable companies include Aligos Therapeutics (ALGS), MDxHealth (MDXH), Radiopharm Theranostics (RADX), BioXcel Therapeutics (BTAI), and Gossamer Bio (GOSS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does OSR compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 455.56%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aligos Therapeutics has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market. Comparatively, OSR has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

Aligos Therapeutics has a net margin of -241.01% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
OSR	-593.15%	-8.36%	-6.24%

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 55.3% of OSR shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 36.9% of OSR shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Aligos Therapeutics has higher revenue and earnings than OSR. Aligos Therapeutics is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$31.52M	1.37	-$24.19M	-$7.30	N/A
OSR	$2.91M	3.02	-$27.06M	-$0.37	N/A

In the previous week, OSR had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 3 mentions for OSR and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.46 beat OSR's score of 0.03 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OSR	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aligos Therapeutics beats OSR on 10 of the 17 factors compared between the two stocks.

How does OSR compare to MDxHealth?

OSR (NASDAQ:OSRH) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

MDxHealth has a net margin of -33.46% compared to OSR's net margin of -593.15%. MDxHealth's return on equity of 0.00% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
MDxHealth	-33.46%	N/A	-24.25%

OSR has higher earnings, but lower revenue than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$2.91M	3.02	-$27.06M	-$0.37	N/A
MDxHealth	$107.88M	0.34	-$33.52M	-$0.72	N/A

55.3% of OSR shares are owned by institutional investors. 36.9% of OSR shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

OSR has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

In the previous week, MDxHealth had 4 more articles in the media than OSR. MarketBeat recorded 7 mentions for MDxHealth and 3 mentions for OSR. OSR's average media sentiment score of 0.03 beat MDxHealth's score of -0.18 indicating that OSR is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OSR	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MDxHealth	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

MDxHealth has a consensus price target of $2.17, suggesting a potential upside of 192.28%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts clearly believe MDxHealth is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

OSR and MDxHealth tied by winning 8 of the 16 factors compared between the two stocks.

How does OSR compare to Radiopharm Theranostics?

OSR (NASDAQ:OSRH) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Radiopharm Theranostics has higher revenue and earnings than OSR.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$2.91M	3.02	-$27.06M	-$0.37	N/A
Radiopharm Theranostics	$3.63M	9.71	-$24.83M	N/A	N/A

Radiopharm Theranostics has a consensus price target of $11.00, indicating a potential upside of 350.82%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

55.3% of OSR shares are held by institutional investors. 36.9% of OSR shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, OSR had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 3 mentions for OSR and 2 mentions for Radiopharm Theranostics. OSR's average media sentiment score of 0.03 beat Radiopharm Theranostics' score of 0.00 indicating that OSR is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OSR	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OSR has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market.

Radiopharm Theranostics has a net margin of 0.00% compared to OSR's net margin of -593.15%. Radiopharm Theranostics' return on equity of 0.00% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
Radiopharm Theranostics	N/A	N/A	N/A

Summary

Radiopharm Theranostics beats OSR on 10 of the 14 factors compared between the two stocks.

How does OSR compare to BioXcel Therapeutics?

OSR (NASDAQ:OSRH) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

55.3% of OSR shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 36.9% of OSR shares are owned by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

OSR has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

OSR has higher revenue and earnings than BioXcel Therapeutics. OSR is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$2.91M	3.02	-$27.06M	-$0.37	N/A
BioXcel Therapeutics	$742K	32.09	-$69.90M	-$3.79	N/A

In the previous week, OSR had 3 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 3 mentions for OSR and 0 mentions for BioXcel Therapeutics. OSR's average media sentiment score of 0.03 beat BioXcel Therapeutics' score of 0.00 indicating that OSR is being referred to more favorably in the media.

Company	Overall Sentiment
OSR	Neutral
BioXcel Therapeutics	Neutral

OSR has a net margin of -593.15% compared to BioXcel Therapeutics' net margin of -9,549.87%. BioXcel Therapeutics' return on equity of 0.00% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%

BioXcel Therapeutics has a consensus target price of $11.00, indicating a potential upside of 1,346.23%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

OSR beats BioXcel Therapeutics on 10 of the 16 factors compared between the two stocks.

How does OSR compare to Gossamer Bio?

OSR (NASDAQ:OSRH) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

OSR has higher earnings, but lower revenue than Gossamer Bio. OSR is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$2.91M	3.02	-$27.06M	-$0.37	N/A
Gossamer Bio	$53.29M	0.77	-$170.37M	-$0.70	N/A

OSR has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market.

In the previous week, Gossamer Bio had 1 more articles in the media than OSR. MarketBeat recorded 4 mentions for Gossamer Bio and 3 mentions for OSR. Gossamer Bio's average media sentiment score of 0.42 beat OSR's score of 0.03 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OSR	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gossamer Bio	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gossamer Bio has a consensus price target of $3.20, indicating a potential upside of 1,728.57%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

55.3% of OSR shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 36.9% of OSR shares are held by company insiders. Comparatively, 3.7% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Gossamer Bio has a net margin of -235.00% compared to OSR's net margin of -593.15%. Gossamer Bio's return on equity of 0.00% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
Gossamer Bio	-235.00%	N/A	-112.04%

Summary

Gossamer Bio beats OSR on 11 of the 16 factors compared between the two stocks.

Get OSR News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OSRH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OSRH vs. The Competition

Export

Metric	OSR	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.78M	$3.99B	$7.29B	$12.71B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-0.68	11.78	271.39	24.10
Price / Sales	3.02	1,299.82	604.58	77.05
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	0.05	17.27	11.18	6.40
Net Income	-$27.06M	-$22.72M	$3.46B	$348.28M
7 Day Performance	-57.63%	2.91%	1.98%	0.92%
1 Month Performance	-40.87%	9.75%	7.32%	5.10%
1 Year Performance	-51.46%	54.82%	24.76%	16.16%

OSR Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OSRH OSR	1.3672 of 5 stars	$0.25 -9.7%	N/A	-46.2%	$8.78M	$2.91M	N/A	N/A
ALGS Aligos Therapeutics	2.7857 of 5 stars	$6.89 +1.8%	$38.50 +458.8%	-34.6%	$43.03M	$2.19M	N/A	90
MDXH MDxHealth	2.1286 of 5 stars	$0.81 +74.9%	$2.83 +250.7%	-77.4%	$39.99M	$107.88M	N/A	300	Analyst Forecast High Trading Volume
RADX Radiopharm Theranostics	2.7775 of 5 stars	$2.56 -3.4%	$11.00 +329.7%	-57.0%	$37.01M	$2.35M	N/A	N/A
BTAI BioXcel Therapeutics	1.3389 of 5 stars	$1.19 +5.3%	$11.00 +824.4%	-83.9%	$36.74M	$640K	N/A	90	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OSRH) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OSR (OSRH) Competitors

OSRH vs. ALGS, MDXH, RADX, BTAI, and GOSS

How does OSR compare to Aligos Therapeutics?

Summary

How does OSR compare to MDxHealth?

Summary

How does OSR compare to Radiopharm Theranostics?

Summary

How does OSR compare to BioXcel Therapeutics?

Summary

How does OSR compare to Gossamer Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSRH vs. The Competition

OSR Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OSR (OSRH) Competitors

OSRH vs. ALGS, MDXH, RADX, BTAI, and GOSS

How does OSR compare to Aligos Therapeutics?

Do analysts recommend ALGS or OSRH?

Which has more risk & volatility, ALGS or OSRH?

Is ALGS or OSRH more profitable?

Do insiders and institutionals believe in ALGS or OSRH?

Which has better valuation & earnings, ALGS or OSRH?

Does the media favor ALGS or OSRH?

Summary

How does OSR compare to MDxHealth?

Is OSRH or MDXH more profitable?

Which has better earnings and valuation, OSRH or MDXH?

Do institutionals and insiders hold more shares of OSRH or MDXH?

Which has more volatility and risk, OSRH or MDXH?

Does the media prefer OSRH or MDXH?

Do analysts prefer OSRH or MDXH?

Summary

How does OSR compare to Radiopharm Theranostics?

Which has better earnings and valuation, OSRH or RADX?

Do analysts rate OSRH or RADX?

Do insiders and institutionals believe in OSRH or RADX?

Does the media prefer OSRH or RADX?

Which has more risk and volatility, OSRH or RADX?

Is OSRH or RADX more profitable?

Summary

How does OSR compare to BioXcel Therapeutics?

Do institutionals and insiders believe in OSRH or BTAI?

Which has more volatility and risk, OSRH or BTAI?

Which has higher earnings and valuation, OSRH or BTAI?

Does the media refer more to OSRH or BTAI?

Is OSRH or BTAI more profitable?

Do analysts prefer OSRH or BTAI?

Summary

How does OSR compare to Gossamer Bio?

Which has stronger earnings and valuation, OSRH or GOSS?

Which has more risk and volatility, OSRH or GOSS?

Does the media prefer OSRH or GOSS?

Do analysts recommend OSRH or GOSS?

Do institutionals & insiders believe in OSRH or GOSS?

Is OSRH or GOSS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSRH vs. The Competition

OSR Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools